Abbott Laboratories
ABT
$105.70
+0.09%
Abbott Laboratories is a diversified healthcare company that develops and manufactures medical devices, diagnostics, nutritional products, and branded generic pharmaceuticals, serving patients and healthcare systems globally. As a market leader in several categories, including continuous glucose monitoring (FreeStyle Libre) and cardiovascular devices, Abbott differentiates itself through its broad portfolio and strong innovation pipeline. The current investor narrative centers on the company's recovery from a challenging 2025, marked by a guidance cut in early 2026 that overshadowed a Q1 earnings beat, while recent strategic moves such as the Exact Sciences acquisition and a robust device pipeline fuel optimism for long-term growth. Despite near-term headwinds, Abbott's 54-year dividend growth streak and defensive healthcare positioning continue to attract income-focused investors.…
ABT
Abbott Laboratories
$105.70
Related headlines
Investment Opinion: Should I buy ABT Today?
We rate ABT as a Buy, driven by its strong revenue growth, margin expansion, and attractive forward valuation. The consensus 'Buy' rating and average target of $118.42 support this view, implying 12% upside. Key evidence includes Q1 revenue growth of 7.8%, gross margin improvement to 56.3%, TTM free cash flow of $7.38B, and a forward P/E of 17.4x, which is below the industry average. The company's defensive healthcare positioning and 54-year dividend growth streak add to its appeal. However, the thesis could be invalidated if the guidance cut signals prolonged weakness, leading to further earnings downgrades. This Buy would be upgraded if the forward P/E drops below 15x or if revenue growth accelerates above 10%, while a downgrade to Hold would occur if the company misses Q2 earnings or if the Exact Sciences integration faces major issues. Overall, ABT appears undervalued relative to its growth prospects, with the forward P/E at a discount to its historical range, making it an attractive long-term investment.
Sign up to view all
ABT 12-Month Price Forecast
The AI model assesses ABT as bullish with medium confidence, driven by solid revenue growth, margin expansion, and a reasonable forward valuation. The recent guidance cut introduces uncertainty, but the company's defensive nature and strong cash flow provide a buffer. The stance would be upgraded to high confidence if Q2 earnings show accelerating growth and the company raises guidance. Conversely, a downgrade to neutral would occur if the company misses revenue estimates or if the Exact Sciences integration faces significant delays.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Abbott Laboratories's 12-month outlook, with a consensus price target around $118.42 and implied upside of +12.0% versus the current price.
Average Target
$118.42
0 analysts
Implied Upside
+12.0%
vs. current price
Analyst Count
—
covering this stock
Price Range
$103 - $135
Analyst target range
Abbott is covered by 24 analysts, with a consensus recommendation of 'Buy' and a mean recommendation score of 1.67 (where 1 is Strong Buy and 5 is Sell). The average price target is $118.42, implying an upside of 12.0% from the current price of $105.70. The analyst sentiment is bullish, with no Sell ratings and a majority of Buy or Overweight ratings, reflecting confidence in the company's long-term prospects despite near-term challenges. The target price range spans from $103.00 (low) to $135.00 (high), indicating a wide dispersion of views. The high target of $135 assumes a successful execution of the Exact Sciences acquisition and robust growth in Medical Devices, potentially driving earnings above consensus. The low target of $103 suggests concerns about ongoing margin pressure or slower-than-expected recovery in diagnostics. Recent ratings actions have been predominantly positive, with firms like Evercore ISI, Piper Sandler, and Barclays reaffirming or maintaining their bullish stances, while no downgrades have been reported in the last six months. This pattern suggests analysts are becoming more confident in Abbott's ability to navigate its current headwinds and deliver on its growth initiatives.
Bulls vs Bears: ABT Investment Factors
Abbott presents a mixed picture: strong operational fundamentals with revenue growth, margin expansion, and robust cash flow are offset by a recent guidance cut and a premium valuation. The bull case is supported by a forward P/E of 17.4x and analyst optimism, while the bear case highlights the trailing P/E premium and near-term earnings pressure. Currently, the evidence slightly favors the bulls due to the company's defensive nature and growth prospects, but the key tension lies in whether the guidance cut is a temporary setback or a sign of deeper issues. If Abbott can deliver on its recovery and integrate Exact Sciences successfully, the stock has significant upside; otherwise, the premium valuation could compress further.
Bullish
- Strong Q1 Revenue Growth: Q1 2026 revenue grew 7.8% YoY to $11.16B, driven by Medical Devices ($5.54B) and Diagnostics ($6.20B), showing broad-based demand. This growth outpaces the healthcare sector average and supports the company's recovery narrative.
- Margin Expansion and Efficiency: Gross margin improved to 56.3% in Q1 2026 from 52.6% a year ago, while operating margin rose to 16.5% from 16.3%. This indicates successful cost management and a favorable product mix, enhancing profitability.
- Robust Free Cash Flow Generation: TTM free cash flow stands at $7.38B, with Q1 operating cash flow of $1.32B comfortably covering the $1.10B dividend payment. This financial strength underpins the 54-year dividend growth streak and provides flexibility for strategic investments.
- Attractive Forward Valuation: The forward P/E of 17.4x is well below the trailing P/E of 33.5x, implying the market expects significant earnings recovery. This discount to historical norms suggests potential upside if the company meets growth expectations.
Bearish
- Guidance Cut Overshadows Earnings: In April 2026, Abbott cut its annual profit outlook despite a Q1 earnings beat, causing the stock to crack. This suggests near-term headwinds that may persist, undermining investor confidence.
- High Trailing P/E Premium: The trailing P/E of 33.5x is 52% above the industry average of 22x, indicating the stock is not cheap on current earnings. This premium may compress if growth fails to materialize as expected.
- Negative PEG Ratio: The PEG ratio of -0.65 reflects expected earnings declines in the near term, making the stock appear overvalued relative to its growth prospects. This could deter growth-oriented investors.
- Underperformance vs. Market: ABT has declined 16.2% over the past year, significantly underperforming the S&P 500's +18.2% gain. This persistent weakness may indicate structural issues or a loss of investor favor.
ABT Technical Analysis
Abbott's stock has been in a pronounced downtrend over the past year, with the price declining 16.2% from a year ago, significantly underperforming the S&P 500's +18.2% gain. The current price of $105.70 sits at 39.4% of its 52-week range (between $81.97 low and $137.49 high), indicating the stock is closer to its lows than highs, reflecting persistent selling pressure. This positioning suggests the market is pricing in fundamental concerns, but also offers potential value if the company can stabilize. The stock's beta of 0.61 indicates it is less volatile than the broader market, which may appeal to risk-averse investors, but it also means the stock has not participated in the market's upside.
Beta
0.61
0.61x market volatility
Max Drawdown
-39.6%
Largest decline past year
52-Week Range
$82-$137
Price range past year
Annual Return
-16.2%
Cumulative gain past year
| Period | ABT Return | S&P 500 |
|---|---|---|
| 1m | +14.7% | +0.3% |
| 3m | +18.2% | +4.0% |
| 6m | -3.3% | +8.3% |
| 1y | -16.2% | +20.2% |
| ytd | -14.9% | +9.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ABT Fundamental Analysis
Abbott's revenue has shown resilience, with Q1 2026 revenue of $11.16 billion, up 7.8% year-over-year, and a sequential increase from Q1 2025's $10.36 billion. The growth is broad-based, with Medical Devices (the largest segment at $5.54 billion) and Diagnostics ($6.20 billion) leading, while Nutritionals ($2.02 billion) and Established Pharmaceuticals ($1.43 billion) contribute steady but slower growth. The company's gross margin improved to 56.3% in Q1 2026 from 52.6% in the year-ago quarter, reflecting operational efficiencies and a favorable product mix. Net income of $1.08 billion in Q1 2026 was down from $1.33 billion in Q1 2025, but this was due to a one-time tax benefit in the prior year; excluding that, profitability is stable. Operating margin expanded to 16.5% from 16.3% year-over-year, indicating disciplined cost management. Abbott's balance sheet remains solid, with a debt-to-equity ratio of 0.29 and a current ratio of 1.58, providing ample liquidity. Free cash flow for the trailing twelve months was $7.38 billion, and the company generated $1.32 billion in operating cash flow in Q1 2026, covering its dividend payments of $1.10 billion. The payout ratio of 63% is sustainable, and the company's strong cash generation supports its 54-year dividend growth streak.
Quarterly Revenue
$11.2B
2026-03
Revenue YoY Growth
+7.8%
YoY Comparison
Gross Margin
56.3%
Latest Quarter
Free Cash Flow
$7.4B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ABT Overvalued?
Given Abbott's positive net income, the trailing P/E ratio of 33.5x is the primary valuation metric, while the forward P/E of 17.4x indicates the market expects significant earnings growth. The gap between trailing and forward P/E reflects the anticipated recovery from the 2025 earnings trough, driven by new product launches and operational improvements. Abbott's current P/E of 33.5x is above the industry average of 22x, representing a 52% premium, which may be justified by its superior growth prospects and defensive characteristics. However, the PEG ratio of -0.65 is negative due to expected earnings declines in the near term, suggesting the premium is not fully supported by growth. Historically, Abbott's P/E has ranged from 21x to 46x over the past five years, and the current 33.5x is near the middle of that range, indicating the stock is not at extreme valuation levels. The price-to-sales ratio of 4.94x is also above the sector average of 3.5x, but this is consistent with Abbott's premium brand and diversified portfolio.
PE
33.5x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 21x~47x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
19.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks include a debt-to-equity ratio of 0.29, which is manageable, but the company's net income declined in Q1 2026 due to a one-time tax benefit in the prior year, masking underlying stability. The payout ratio of 63% is sustainable, yet any prolonged earnings weakness could pressure the dividend growth streak. Additionally, the negative PEG ratio signals that near-term earnings are expected to decline, which could lead to valuation compression if not reversed. The company's reliance on continued growth in Medical Devices and Diagnostics, which together account for over half of revenue, exposes it to product-specific risks such as competitive pressures or regulatory changes. Market risks include a beta of 0.61, indicating lower volatility but also underperformance during market rallies, as seen in the past year. The stock trades at a 52% premium to the industry average P/E, making it vulnerable to multiple compression if growth disappoints. The recent guidance cut has already triggered a sell-off, and further negative revisions could exacerbate losses. Competitive threats from emerging players in continuous glucose monitoring and cardiovascular devices could erode market share. In a worst-case scenario, if Abbott fails to execute its recovery plan and the Exact Sciences acquisition underperforms, the stock could decline to its 52-week low of $81.97, representing a 22.5% drop from the current price. This would be compounded by a potential dividend cut if cash flow deteriorates, though the current payout ratio suggests this is unlikely. Historically, the stock has experienced a max drawdown of -39.57%, indicating that significant downside is possible in adverse conditions.
FAQ
Key risks include: 1) Financial: The payout ratio of 63% is sustainable, but any prolonged earnings decline could pressure the dividend. 2) Competitive: Intense competition in CGM and cardiovascular devices could erode market share. 3) Macro: With a beta of 0.61, the stock is less volatile but may underperform in strong markets. 4) Company-specific: The Exact Sciences acquisition carries integration risks, and the recent guidance cut highlights near-term uncertainty. The most severe risk is a further guidance cut, which could drive the stock to the 52-week low of $81.97, a 22.5% downside.
The 12-month forecast is moderately bullish, with a base case probability of 50% targeting $110-$120, aligning with the analyst average of $118.42. The bull case (30% probability) targets $118-$135, driven by successful execution and strong growth. The bear case (20% probability) targets $82-$103, reflecting continued headwinds. The most likely scenario is the base case, assuming revenue growth of 7-8% and margin stability. Investors should monitor Q2 earnings and the Exact Sciences integration for signs of which scenario will unfold.
ABT's trailing P/E of 33.5x is 52% above the industry average of 22x, suggesting it is overvalued on current earnings. However, the forward P/E of 17.4x indicates the market expects significant earnings growth, making it appear undervalued on a forward basis. The PEG ratio of -0.65 is negative due to expected earnings declines, which complicates the picture. Historically, the stock has traded between 21x and 46x P/E, and the current 33.5x is near the middle, suggesting it is fairly valued. The market is pricing in a recovery, and if that fails to materialize, the stock could be overvalued.
ABT is a good buy for investors with a long-term horizon, given its strong revenue growth of 7.8% YoY, margin expansion, and a forward P/E of 17.4x, which is below the industry average. The analyst consensus is 'Buy' with an average target of $118.42, implying 12% upside. However, the recent guidance cut and high trailing P/E of 33.5x pose risks. For value investors, the stock may be attractive after the recent decline, but for those seeking immediate growth, the near-term headwinds could be a concern. Overall, it is a solid addition to a diversified portfolio, especially for income-focused investors.
ABT is best suited for long-term investment, given its defensive healthcare business, strong cash flow, and dividend growth. The stock's beta of 0.61 indicates lower volatility, making it less attractive for short-term traders seeking quick gains. The recent 14.7% gain over the past month suggests some short-term momentum, but the overall trend is still down. For long-term investors, the forward P/E of 17.4x and a 54-year dividend growth streak provide a compelling case. A minimum holding period of 3-5 years is recommended to ride out near-term volatility and benefit from the company's growth initiatives.